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ORIGINAL RESEARCH
Relationship Between Dietary Magnesium 
Intake and Incident Heart Failure 
Among Older Women: The WHI
Wen-Chih Wu , MD, MPH; Mengna Huang, PhD; Tracey H. Taveira, PharmD; Mary B. Roberts, MS;  
Lisa W. Martin, MD; Gregory A. Wellenius, ScD; Karen C. Johnson, MD; JoAnn E. Manson, MD, DrPH;  
Simin Liu, ScD, MD; Charles B. Eaton, MD
BACKGROUND: Women represent a large proportion of the growing heart failure (HF) epidemic, yet data are lacking regarding 
optimal dietary and lifestyle prevention strategies for them. Specifically, the association between magnesium intake and HF in 
a multiracial cohort of women is uncertain.
METHODS AND RESULTS: We included 97 725 postmenopausal women from the WHI (Women’s Health Initiative) observational 
studies and placebo arms of the hormone trial. Magnesium intake was measured at baseline by a 122- item validated food- 
frequency questionnaire and stratified into quartiles based on diet only, total intake (diet with supplements), and residual intake 
(calibration by total energy). Incident hospitalized HF (2153 events, median follow- up 8.1 years) was adjudicated by medical 
record abstraction. In Cox proportional hazards models, we evaluated the association between magnesium intake and HF ad-
justing for potential confounders. Analyses were repeated on a subcohort (n=18 745; median- follow- up, 13.2 years) for whom 
HF cases were subclassified into preserved ejection fraction (526 events), reduced ejection fraction (291 events) or unknown 
(168 events). Most women were white (85%) with a mean age of 63. Compared with the highest quartile of magnesium intake, 
women in the lowest quartile had an increased risk of incident HF, with adjusted hazard ratios of 1.32 (95% CI, 1.02–1.71) for 
diet only (P trend=0.03), 1.26 (95% CI, 1.03–1.56) for total intake, and 1.31 (95% CI, 1.02–1.67) for residual intake. Results 
did not significantly vary by race. Subcohort analyses showed low residual magnesium intake was associated with HF with 
reduced ejection fraction (hazard ratio, 1.81, lowest versus highest quartile; 95% CI, 1.08–3.05) but not HF with preserved 
ejection fraction.
CONCLUSIONS: Low magnesium intake in a multiracial cohort of postmenopausal women was associated with a higher risk of 
incident HF, especially HF with reduced ejection fraction.
Key Words: heart failure with preserved ejection fraction ■ heart failure with reduced ejection fraction ■ residual method  
■ total magnesium
In 2015, it was estimated that 5.7 million individuals over the age of 20 in the United States have been di-agnosed with heart failure (HF).1 Of those diagnosed 
with HF, 3  million were women. It is estimated that 
455 000 new HF cases will be diagnosed in women 
older than 45  years each year.1 However, data are 
lacking regarding optimal dietary and lifestyle preven-
tion strategies for HF in this population.
Low serum and dietary magnesium have been 
associated with risk factors of HF, such as coronary 
heart disease,2 insulin resistance,3 type 2 diabetes 
mellitus,4 hypertension,5,6 and atrial fibrillation.7 Dietary 
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magnesium intake is also associated with HF hospi-
talizations in African- Americans in the Jackson Heart 
Study8 and could potentially be a target for lifestyle 
modification and HF prevention, as >80% of older 
adults in the United States are not meeting dietary 
magnesium recommendations.9 However, it is known 
that racial differences exist in magnesium intake,9 and 
magnesium intake requirements are different for men 
and women.10 Yet data are lacking on the relationship 
between dietary magnesium and HF in a multiracial 
cohort of women. Moreover, the relationship between 
magnesium intake and the type of HF (HF with pre-
served ejection fraction [HFpEF] or HF with reduced 
ejection fraction [HFrEF]) is unknown and would be im-
portant to understand potential mechanistic pathways 
of this relationship.
Because risk factors and the incidence and type of 
HF vary by women of different race,11 understanding 
the association between magnesium intake and the 
risk of developing HF and its subtypes in a multiracial 
cohort of women represents a novel and potentially 
useful approach to identifying women at increased 
risk for target prevention. The purpose of this study 
is to examine the relationship between dietary mag-
nesium and incident HF in the WHI (Women’s Health 
Initiative) study. We hypothesize that low dietary mag-
nesium intake will be associated with an increased 
risk of incident hospitalizations for HF. The pro-
spective design of the WHI, the long follow- up, and 
availability of comprehensive dietary information and 
lifestyle factors in this clinically well- characterized 
multiracial population allow us the unique opportunity 
to rigorously test this hypothesis in postmenopausal 
women.
METHODS
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-
dentiality protocols may be sent to the WHI at https://
www.whi.org/resea rcher s/data/Pages/ Home.aspx.
Study Population
The WHI recruited a total of 161 808 postmenopau-
sal women aged 50 to 79 years at 40 clinical centers 
across the United States between 1993 and 1998, 
including a cohort of 93 676 women in a prospec-
tive observational study (OS) and 68 133 women in 
≥1 of the following 3 clinical trials: hormone therapy, 
calcium and vitamin D, or dietary modification trial.12 
The calcium and vitamin D trial participants were 
recruited from the hormone therapy and dietary 
modification trials. The primary analysis included 
participants of the OS and control arm of the hor-
mone therapy trial who completed baseline physi-
cal examination, demographic, medical history, and 
dietary questionnaires. Overall, baseline character-
istics of participants from the OS and the hormone 
therapy trials were grossly similar except for college 
education (43% versus 32%), income <$20 000 per 
annum (14% versus 21%), mean body mass index 
(BMI; 27.2±5.8 versus 28.4±5.9), recreational physi-
cal activity (13.8±14.4 versus 11.9±13.8  metabolic 
equivalents/week), diabetes mellitus prevalence 
(3.8% versus 5.2%), and multivitamin use (42% ver-
sus 36.0%), respectively. Participants in the dietary 
modification trial were excluded from the analysis, 
CLINICAL PERSPECTIVE
What Is New?
• The association between magnesium intake and 
heart failure in a multiracial cohort of women is 
unknown.
• This study showed that lower dietary intake of 
magnesium was associated with higher inci-
dence rates of hospitalization for heart failure in 
postmenopausal women.
• In subgroup analyses, low dietary magnesium 
was associated with incident hospitalization for 
heart failure with reduced ejection fraction but 
not preserved ejection fraction.
What Are the Clinical Implications?
• These results suggest that ≈75% of postmen-
opausal women in this cohort have a median 
magnesium intake below US Recommended 
Daily Allowance levels, and a quarter of them 
are at increased risk of incident heart failure 
based on their dietary magnesium intake.
Nonstandard Abbreviations and Acronyms
ARIC Atherosclerosis Risk in Communities
BMI body mass index
HF heart failure
HFpEF  heart failure with preserved ejection 
fraction
HFrEF  heart failure with reduced ejection 
fraction
HR hazard ratio
JHS Jackson Heart Study
LV left ventricular
OS observational study
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as baseline diet would not reflect a stable diet, and 
because of potential selection bias of a high per-
centage of dietary fat as an inclusion criterion for 
the dietary modification trial. Participants with HF 
at baseline were excluded as established by self- 
reporting on the eligibility screening and baseline 
medical history questionnaires, in which participants 
were asked to self- identify if they have ever been 
told by a doctor that they have HF or congestive HF. 
Participants were also excluded if they had a base-
line energy intake outside the range of 600 kcal to 
5000 kcal/day because of potential misclassification 
(Figure 1).13 Given that this project used only deiden-
tified data from the WHI, it met the criteria for ex-
emption by the Providence Veterans Affairs Medical 
Center Institutional Review Board.
Exposure: Dietary Magnesium
Dietary magnesium intake was derived using a semi-
quantitative food frequency questionnaire that as-
sessed nutrient intake over the past 3  months.13–15 
The nutrient database for the WHI food frequency 
questionnaire was adapted from the University of 
Minnesota Nutrition Coding Center (Minneapolis, 
MN) nutrient database.16 The food frequency ques-
tionnaire was administered to all WHI participants at 
baseline. We used the baseline unadjusted measure-
ments for dietary magnesium, as well as the residual 
method in which dietary magnesium was linearly 
regressed on calibrated total energy intake, and the 
residuals were used as the independent variable (ex-
posure) in the subsequent analysis.17 Total energy 
intake was calibrated using the equation derived 
from a study using recovery biomarkers previously 
in a subsample of the OS participants, accounting 
for age, race, and BMI.18 Both dietary magnesium 
intake and residual magnesium intake were divided 
into quartiles.
Because participants could also ingest magne-
sium through oral supplementation, we constructed 
a total magnesium variable as a sensitivity analy-
sis, which is the sum of dietary and supplemental 
magnesium. Data on magnesium supplement were 
obtained through the inventory of the patient’s med-
ication and supplement bottles brought in to the in-
terviewer at baseline clinic visits and coded into a 
database through a standardized inventory proce-
dure. In centers without direct access to a computer, 
a standardized interviewer- administered form was 
used to collect the information.19,20 Because supple-
mental intake was measured by a separate method-
ology, we were not able to use the residual method 
for the total magnesium variable.
Outcome: Incident HF Hospitalizations
The primary outcome was incident hospitalization for 
HF, which was ascertained yearly in WHI by medi-
cal record abstraction of all self- report hospitaliza-
tions and classified by trained adjudicators using 
the standardized methodology as previously de-
scribed.21 Hospitalized HF requiring and/or occurring 
during hospitalization required physician diagnosis of 
new- onset or worsened HF on the reported hospital 
admission and ≥1 of the following 4 criteria: HF diag-
nosed by physician and receiving medical treatment 
for HF; symptoms plus documentation in the current 
medical record of a history of an imaging procedure 
showing impaired left ventricular (LV) systolic or di-
astolic LV function; pulmonary edema/congestion on 
chest radiograph on the current admission; or dilated 
ventricle(s) or “poor” LV or right ventricular function 
by echocardiography, radionuclide ventriculography, 
Figure 1. Flow diagram of WHI participants in the analysis. 
FFQ indicates food frequency questionnaire; OS, observational 
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or other contrast ventriculography or evidence of LV 
diastolic dysfunction. This method was found to have 
a 79% agreement rate comparing central adjudicated 
HF and local adjudication.21
In 2010, a subcohort of the WHI OS and hormone 
therapy trial oversampled for black and Hispanic par-
ticipants, were retrospectively evaluated for HFpEF 
and HFrEF and then followed until March 31, 2018. Of 
the 44 174 participants in this subcohort, 18 745 were 
included in a subgroup analysis in this study to deter-
mine the etiology of HFpEF or HFrEF (secondary out-
come) using the same exclusion criteria as the primary 
analysis (Figure S1).
Statistical Analysis
Descriptive statistics were generated for baseline co-
variates within quartiles of unadjusted dietary magne-
sium intake. Specifically, mean and SD were generated 
as descriptive statistics for each continuous covariate, 
while frequency and percentages were generated for 
each categorical covariate.
We used Cox proportional hazards models to esti-
mate the hazard ratios (HRs) of HF for each quartile of 
magnesium intake, using the highest intake quartile as 
reference. Analyses were conducted first for quartiles 
of unadjusted magnesium intake adjusted for total 
energy intake, followed by quartiles of residual mag-
nesium intake and then by quartiles of total magne-
sium intake accounting for supplemental magnesium. 
The time to HF event was calculated as the interval 
between baseline and incident HF, with censoring at 
last follow- up visit or death. Potential selection bias 
was accounted for by inverse probability weighting by 
membership in the OS or hormone therapy cohorts. 
The proportional hazard assumption was checked 
by visual examination of the survival curves. Potential 
confounders measured at baseline, determined on the 
basis of previous knowledge and prior literature, were 
included in the multivariable Cox proportional hazards 
models if the covariate was determined to be not on 
the causal pathway. As such, we used a sequential 
approach to analysis in which we constructed 5 sub-
models, each nested within the next (Table S1). In the 
final model, we adjusted for age; race; smoking sta-
tus; BMI; dyslipidemia; systolic blood pressure; prior 
coronary heart disease; atrial fibrillation; heart rate; 
hypertension; diabetes mellitus; dietary intake (so-
dium, potassium, calcium, alcohol, protein, phospho-
rus, and calibrated total energy, as these factors may 
influence body magnesium handling and storage)22–24; 
and medications, such as diuretics (hydrochlorothia-
zide, furosemide), mineralocorticoid receptor antag-
onists, angiotensin- converting enzyme inhibitors or 
angiotensin receptor blockers, magnesium containing 
laxatives, proton pump inhibitors, or multivitamins, as 
these medications may affect magnesium exposure 
and potentially the outcome of HF. Sensitivity analyses 
were conducted, (1) excluding participants on diuret-
ics and (2) excluding the first year of follow- up from 
the analysis to test the robustness of the findings. 
Stratified analyses were conducted by race (white ver-
sus nonwhite) and by using race- specific quartiles of 
magnesium intake.
We tested for the interaction on the multiplicative 
scale between dietary magnesium intake with age 
and race, as well as with comorbid diseases that 
predispose patients to hypomagnesemia (diabetes 
mellitus), respectively, and incident HF by including 
product terms for each interaction separately, in the 
full model. Trend testing across magnesium quar-
tiles was conducted using the median magnesium 
value within each quartile. A subgroup analysis was 
conducted in the 18 745 participants from the 2010 
subcohort to determine the subtype of HF (HFpEF or 
HFrEF).
All analyses were conducted in SAS version 9.4 
(SAS Institute Inc., Cary, NC).
RESULTS
Among 103  240 participants in the WHI OS or the 
placebo arm of the hormone therapy trials, 97  725 
were included in the primary analysis. We observed 
2153 HF cases over a median follow- up of 8.1 years. 
The median dietary magnesium intake across quar-
tiles were 149 mg/day for women in the lowest quar-
tile (mean 144.4±26.9), 212 mg/day (mean 212.3±17.1) 
for those in the second quartile, 272 mg/day (mean 
273.3±19.3) for the third quartile, and 363  mg/day 
(mean 383.1±69.1) for the highest quartile of intake. 
Women in the lower quartiles of dietary magnesium 
intake were more likely to be aged 70 years or older, 
less likely to be white, had lower education and in-
come, more likely to be current smokers, had lower 
recreational physical activity and slightly higher sys-
tolic blood pressure, and more likely to have hyper-
tension, diabetes mellitus, dyslipidemia, and prior 
coronary heart disease. They also had lower dietary 
intake of alcohol, calcium, phosphorus, protein, po-
tassium, sodium, vitamin D, and multivitamins and 
had lower total energy; and higher use of angiotensin- 
converting enzyme inhibitors, diuretics, and proton 
pump inhibitors (Table 1).
Compared with those in the highest quartile of un-
adjusted dietary magnesium intake, women in the 
lowest quartile had 1.32 times (95% CI, 1.02–1.71) the 
hazard of incident HF in a fully adjusted model (Table 2), 
the hazards of which decreased in a linear fashion 
with higher dietary magnesium intake (P value for lin-
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Table 1. Demographic and Physiologic Characteristics (n=97 725)
Uncalibrated Baseline Dietary Magnesium Intake Quartiles
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N 21 869 25 002 25 475 25 379
Magnesium median, mg/d* 149 212 272 363
HF cases 522 558 551 522
HF incidence† 3.10 (3.09–3.12) 2.84 (2.83–2.86) 2.73 (2.72–2.74) 2.59 (2.57–2.60)
Age (y) continuous
Mean (SD) 63.7 (7.4) 63.6 (7.3) 63.7 (7.3) 63.4 (7.3)
Age (y) categorical
<50–59 6904 (31.6) 7920 (31.7) 7926 (31.1) 8299 (32.7)
60–69 9456 (43.2) 11 042 (44.2) 11 390 (44.7) 11 283 (44.5)
70 to ≥79 5509 (25.2) 6040 (24.2) 6159 (24.2) 5797 (22.8)
Race
American Indian 143 (0.7) 95 (0.4) 88 (0.4) 85 (0.3)
Asian 870 (4.0) 727 (2.9) 553 (2.2) 514 (2.0)
Black 2903 (13.3) 1793 (7.2) 1322 (5.2) 1316 (5.2)
Hispanic 1258 (5.8) 935 (3.8) 690 (2.7) 746 (3.0)
White‡ 16 403 (75.0) 21 181 (84.7) 22 577 (88.6) 22 447 (88.4)
Other 292 (1.3) 271 (1.1) 245 (1.0) 271 (1.1)
Education
Less than high school 1844 (8.5) 1234 (5.0) 928 (3.7) 836 (3.3)
High school 7190 (33.2) 6873 (27.7) 6157 (24.4) 5281 (21.0)
Some college 6030 (27.8) 6864 (27.7) 6710 (26.5) 6390 (25.4)
College or greater 6625 (30.6) 9828 (39.6) 11 487 (45.4) 12 665 (50.3)
Income
<20 000 4334 (19.8) 3684 (14.7) 3169 (12.4) 3295 (13.0)
20 000 to <35 000 5059 (23.1) 5518 (22.1) 5518 (21.7) 5383 (21.2)
35 000 to <50 000 3996 (18.3) 4669 (18.7) 4868 (19.1) 4947 (19.5)
50 000 to <75 000 3543 (16.2) 4675 (18.7) 5039 (19.8) 4959 (19.5)
>75 000 3257 (14.9) 4658 (18.6) 5155 (20.2) 5052 (19.9)
Missing 1680 (7.7) 1798 (7.2) 1726 (6.8) 1743 (6.9)
Smoking status
Never 11 048 (51.3) 12 338 (50.1) 12 573 (50.0) 12 862 (51.4)
Past 8435 (39.2) 10 569 (42.9) 11 157 (44.4) 11 001 (43.9)
Current 2056 (9.6) 1729 (7.0) 1422 (5.7) 1172 (4.7)
Body mass index, kg/m2
Mean (SD) 27.5 (5.9) 27.2 (5.7) 27.2 (5.8) 27.4 (6.0)
Weight, kg
Mean (SD) 71.5 (17.0) 71.3 (16.5) 71.7 (16.5) 72.9 (17.2)
Heart rate, beats per min
Mean (SD) 70 (12.4) 69 (12.3) 69 (11.9) 69 (12.0)
Systolic blood pressure, mm Hg
Mean (SD) 128 (18.2) 127 (17.9) 126 (17.8) 127 (17.7)
Diastolic blood pressure, mm Hg
Mean (SD) 75 (9.4) 75 (9.2) 75 (9.3) 75 (9.2)
Waist/hip ratio
Mean (SD) 0.81 (0.09) 0.81 (0.08) 0.80 (0.08) 0.81 (0.08)
Total energy expenditure from recreational physical activity (METS/wk)
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Uncalibrated Baseline Dietary Magnesium Intake Quartiles
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Dietary magnesium intake, mg/d
Mean (SD) 144.4 (26.9) 212.3 (17.1) 273.3 (19.3) 383.1 (69.1)
Supplemental magnesium intake, mg/d
Mean (SD) 63.0 (146.3) 71.4 (149.1) 75.0 (153.9) 78.0 (155.1)
Total magnesium intake, mg/d
Mean (SD) 207.5 (149.6) 283.7 (150.4) 348.2 (155.3) 461.1 (170.8)
Dietary protein intake
Mean (SD) 39.9 (12.1) 55.8 (14.1) 69.9 (16.5) 95.9 (27.5)
Dietary phosphorus intake
Mean (SD) 642.6 (170.3) 939.4 (192.2) 1216.0 (233.4) 1745.7 (467.6)
Potassium, mg/d
Mean (SD) 1553.1 (347.7) 2233.1 (321.8) 2823.3 (381.2) 3840.6 (790.2)
Calcium intake, mg/d
Mean (SD) 434.5 (182.8) 661.1 (235.3) 877.9 (295.7) 1298.6 (504.2)
Vitamin D, μg/d
Mean (SD) 2.3 (1.3) 3.4 (1.8) 4.6 (2.4) 6.9 (4.0)
Sodium intake, mg/d
Mean (SD) 1632.5 (484.7) 2244.1 (583.7) 2775.4 (688.8) 3795.4 (1158.5)
Alcohol, servings/wk
Mean (SD) 1.83 (4.13) 2.42 (4.66) 2.86 (5.29) 3.12 (6.38)
Calibrated total energy, kcal/d
Mean (SD) 2220 (263.9) 2255 (261.0) 2282 (267.1) 2332 (282.7)
Hypertension
Yes 7555 (35.4) 7993 (32.7) 7856 (31.6) 7835 (31.5)
Diabetes mellitus
Yes 980 (4.5) 951 (3.8) 900 (3.5) 1033 (4.1)
Dyslipidemia
Yes 2049 (9.4) 2374 (9.5) 2297 (9.0) 2138 (8.4)
Previous coronary heart disease
Yes 1546 (7.1) 1625 (6.5) 1581 (6.2) 1535 (6.1)
Atrial fibrillation
Yes 960 (4.4) 1031 (4.1) 1079 (4.2) 1092 (4.3)
Angiotensin receptor blockers
Yes 155 (0.7) 196 (0.8) 160 (0.6) 190 (0.8)
Angiotensin- converting enzyme inhibitors
Yes 1869 (8.6) 1960 (7.8) 1872 (7.4) 1745 (6.9)
Multivitamin
Yes 7842 (35.9) 10 231 (40.9) 10 996 (43.2) 11 450 (45.1)
Diuretics
Yes 3270 (15.0) 3379 (13.5) 3153 (12.4) 3042 (12.0)
Laxatives containing magnesium
Yes 26 (0.1) 30 (0.1) 32 (0.1) 30 (0.1)
Proton pump inhibitors
Yes 578 (2.6) 564 (2.3) 491 (1.9) 447 (1.8)
HF indicates heart failure.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†Incidence rate per 1000 person- years’ follow- up (95% CI).
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magnesium intake (HR, 1.31; 95% CI, 1.02–1.67, low-
est versus highest quartile of intake; P- value for linear 
trend=0.04) and slightly attenuated in the total magne-
sium intake accounting for supplemental magnesium 
(HR, 1.26; 95% CI, 1.03, 1.56, lowest versus highest 
quartile of intake; P value for linear trend=0.06) (Table 2). 
Sensitivity analyses excluding participants on diuretic 
therapy (fully adjusted HR, 1.24; 95% CI, 0.92–1.67, 
lowest versus highest quartile of residual magnesium 
intake, n=84 449) or excluding the first year of follow- up 
(fully adjusted HR, 1.36; 95% CI, 1.05–1.76, lowest 
versus highest quartile of residual magnesium intake, 
n=97 077) showed similar HR trends, respectively.
In stratified analyses by race, results remained 
consistent among white women (n=82  608), with 
an adjusted hazard ratio of 1.43 (95% CI, 1.09–1.88, 
lowest versus highest quartile of intake; P value for 
linear trend=0.01) but attenuated and nonsignificant 
among nonwhite women (n=15  117; P value for lin-
ear trend=0.52 unadjusted, and P=0.67 using the 
Table 2. Hazard Ratio of Incident Hospitalized HF (2005) by Quartiles of Magnesium Intake Using Unadjusted, Residual, 
and Total Intake Methods of Magnesium Intake Quantification
Unadjusted Baseline Dietary Magnesium Intake Quartiles* (N=97 725)
Q1 Q2 Q3 Q4
N 21 869 25 002 25 475 25 379
HF cases 522 558 551 522
HF incidence† 3.10 (3.09–3.12) 2.84 (2.83–2.86) 2.73 (2.72–2.74) 2.59 (2.57–2.60)
Hazard Ratio (95% CI)
P for TrendQ1 Q2 Q3 Q4
Unadjusted 1.20 (1.06–1.36) 1.10 (0.98–1.24) 1.06 (0.94–1.19) Referent <0.01
Fully adjusted‡ 1.32 (1.02–1.71) 1.17 (0.96–1.44) 1.08 (0.92–1.27) Referent 0.03
Residual Baseline Dietary Magnesium Intake (Regression on Calibrated Total Energy Intake)§ (N=97 237)||
Q1 Q2 Q3 Q4
N 22 930 24 004 24 861 25 442
HF cases 548 509 532 550
HF incidence† 3.09 (3.08–3.11) 2.70 (2.68–2.71) 2.70 (2.69–2.72) 2.73 (2.72–2.74)
Hazard Ratio (95% CI)
P for TrendQ1 Q2 Q3 Q4
Unadjusted 1.13 (1.01–1.27) 0.99 (0.88–1.11) 0.99 (0.88–1.12) Referent 0.08
Fully adjusted‡ 1.31 (1.02–1.67) 1.08 (0.89–1.32) 1.04 (0.89–1.22) Referent 0.04
Unadjusted Baseline Total Magnesium Intake (Dietary and Supplemental Magnesium)¶ (N=97 725)
Q1 Q2 Q3 Q4
N 21 683 24 368 25 555 26 119
HF cases 556 558 514 525
HF incidence† 3.32 (3.30–3.33) 2.91 (2.89–2.92) 2.54 (2.53–2.55) 2.54 (2.53–2.55)
Hazard Ratio (95% CI)
P for TrendQ1 Q2 Q3 Q4
Unadjusted 1.30 (1.15–1.46) 1.14 (1.01–1.28) 1.00 (0.88–1.13) Referent <0.01
Fully adjusted‡ 1.26 (1.03–1.56) 1.09 (0.93–1.29) 0.96 (0.84–1.11) Referent 0.06
HF indicates heart failure; Q, Quartile.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†Incidence rate per 1000 person- years’ follow- up (95% CI).
‡Model stratified by observational study/hormone trial membership. Model adjusted for age, race, smoking status, body mass index, dyslipidemia, systolic 
blood pressure, prior coronary heart disease, atrial fibrillation, heart rate, hypertension, diabetes mellitus, dietary intake (sodium, potassium, calcium, alcohol, 
protein, phosphorus, calibrated total energy), medications (angiotensin- converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium- 
containing laxatives, proton pump inhibitors), and multivitamins.
§Range of residual dietary magnesium by quartiles: quartile 1: −276 to −68; quartile 2: −67 to −12; quartile 3: −11 to 54; quartile 4: 55–750.
||Sample size changed because of missingness in some variables used to calibrate total energy intake. Calibrated total energy as a variable was not included 
in the analysis using the residual method.
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residual method; Table  3). The interaction terms 
between unadjusted magnesium intake (or residual 
magnesium) and race (P=0.84), age (P=0.37), and 
diabetes mellitus (P=0.65) were not statistically sig-
nificant. Results remained similar when race- specific 
quartiles of magnesium intake were used.
For our subgroup analysis in the 2010 subcohort, 
we included 18 745 participants with 985 HF cases 
(526 HFpEF, 291 HFrEF, and 168 unknown HF type) 
over a median follow- up of 13.2 years (baseline char-
acteristics, Table S2). Lower unadjusted dietary mag-
nesium intake was significantly associated with higher 
hazards of HFrEF (HR=1.76 comparing lowest with 
highest quartile; 95% CI, 1.03–2.98; P value for linear 
trend=0.02) but not HFpEF (HR, 0.74 comparing low-
est with highest quartile; 95% CI, 0.49–1.12; P value 
for linear trend=0.31; Table S3) in the fully adjusted 
model (Figure 2). Results were similar when residual 
dietary magnesium intake was used for both HFpEF 
(P value for linear trend=0.73 across quartiles) and 
HFrEF (P value for linear trend=0.01 across quartiles; 
Table S4). Results were no longer significant after 
accounting for total magnesium intake (adding mag-
nesium supplements): P value for linear trend=0.24 
across quartiles for HFpEF and 0.69 for HFrEF (Table 
S5). Sensitivity analyses excluding participants on 
diuretic therapy (fully adjusted HRs for HFpEF, 0.88; 
95% CI, 0.54–1.41; and for HFrEF, 2.15; 95% CI, 1.19–
3.87; lowest versus highest quartile of residual mag-
nesium intake, n=15  593) or excluding the first year 
of follow- up (fully adjusted HRs for HFpEF, 0.99; 95% 
CI, 0.66–1.49; and for HFrEF, 1.76; 95% CI, 1.04–2.98; 
lowest versus highest quartile of residual magnesium 
intake, n=18 657) showed similar results, respectively.
Table 3. Hazard Ratio of Incident Hospitalized HF (2005) by Race and by Quartiles of Magnesium Intake Using Unadjusted 
and Residual Intake Methods of Magnesium Intake Quantification
Unadjusted Baseline Dietary Magnesium Intake Quartiles*
Q1 Q2 Q3 Q4
Number of HF cases (total number)
White 412 (16 403) 487 (21 181) 497 (22 577) 472 (22 447)
Nonwhite 110 (5466) 71 (3821) 54 (2898) 50 (2932)
HF incidence (95% CI)†
White 3.22 (3.21–3.24) 2.90 (2.89–2.92) 2.76 (2.74–2.77) 2.62 (2.61–2.63)
Nonwhite 2.72 (2.70–2.75) 2.49 (2.46–2.51) 2.50 (2.46–2.53) 2.29 (2.25–2.32)
Adjusted Hazard Ratios (95% CI)‡
P for 
TrendQ1 Q2 Q3 Q4
White 1.43 (1.09–1.88) 1.25 (1.01–1.55) 1.13 (0.95–1.34) Referent 0.01
Non- White 0.75 (0.35–1.62) 0.79 (0.43–1.46) 0.81 (0.48–1.38) Referent 0.52
Residual Baseline Dietary Magnesium Intake (Adjusted for Calibrated Energy)§
Q1 Q2 Q3 Q4
# HF cases (total #)
White 432 (17 263) 440 (20 338) 486 (22 023) 501 (22 552)
Non- White 116 (5667) 69 (3666) 46 (2838) 49 (2890)
HF incidence (95% CI)†
White 3.19 (3.18–3.21) 2.73 (2.71–2.74) 2.77 (2.76–2.78) 2.78 (2.77–2.80)
Non- White 2.77 (2.75–2.80) 2.51 (2.48–2.54) 2.16 (2.13–2.19) 2.28 (2.25–2.31)
Adjusted Hazard Ratios (95% CI)‡
P for 
TrendQ1 Q2 Q3 Q4
White 1.42 (1.09–1.84) 1.14 (0.92–1.40) 1.10 (0.93–1.30) Referent 0.01
Non- White 0.80 (0.37–1.69) 0.81 (0.45–1.48) 0.76 (0.45–1.30) Referent 0.67
HF indicates heart failure; Q, Quartile.
*Range of dietary magnesium (mg/day) by quartiles: quartile 1: 0–181; quartile 2: 182–241; quartile 3: 242–309; quartile 4: 310–1004.
†Incidence rate per 1000 person- years’ follow- up.
‡Model adjusted for age, smoking status, and traditional risk factors (body mass index, systolic blood pressure, prior coronary heart disease, atrial fibrillation, 
heart rate, hypertension, diabetes mellitus, dyslipidemia), dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy 
[not included in the analysis using the residual method]), medications (angiotensin- converting enzyme inhibitors, angiotensin receptor blockers, diuretics, 
magnesium- containing laxatives, proton pump inhibitors), and multivitamins.
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DISCUSSION
In this large, national, multiracial, prospective cohort 
study of postmenopausal women, lower dietary in-
take of magnesium was associated with higher inci-
dence rates of hospitalization for HF. The relationship 
between quartiles of dietary magnesium and incident 
hospitalization for HF did not vary significantly by race, 
age, or presence of diabetes mellitus. In subgroup 
analyses, low dietary magnesium was associated only 
with incident hospitalized HFrEF but not HFpEF.
To our knowledge, this is one of the first studies 
that relates dietary magnesium in postmenopausal 
women to incident HF and its subtypes. Our results 
expand the previous findings that related higher mag-
nesium intake to lower risk of hospitalizion for HF in 
black men and women from the JHS (Jackson Heart 
Study)8 to women of other races. Although our results 
did not vary significantly by race, an attenuation of 
the association between dietary magnesium and HF 
to nonsignificant levels were found in the nonwhite 
women, which contrast the results in the JHS co-
hort. This discrepancy could be related to the differ-
ential dietary magnesium intake9 and distinct risk of 
HF and its subtypes, which has been shown to vary 
by race.11 Nonwhite women in our cohort had lower 
incidence rates of HF compared with whites, all of 
which remained under 1% and could have reduced 
our power to detect a statistically significant differ-
ence across quartiles of magnesium intake. In con-
trast, in the JHS cohort, despite a higher magnesium 
intake (mean of 181 and 474  mg in the lowest and 
highest quartiles of intake, respectively), a younger 
age (mean age, 55  years), and a shorter follow- up 
time (median, 1837 days), the rates of HF admission 
during follow- up remained high, at 1.1% per year. This 
is likely attributable to the high prevalence of diabetes 
mellitus (22%) and obesity (mean BMI, 31.8 kg/m2) in 
the JHS, which conferred the cohort with a high risk 
for HF. Taken together, these findings do not show 
that the association between magnesium intake and 
incident HF significantly vary by race.
Potential mechanisms of the association between 
magnesium intake and HF hospitalizations can be sev-
eral. Low serum and dietary magnesium have been 
associated with risk factors of HF, such as coronary 
disease,2 left ventricular hypertrophy,25 insulin resis-
tance,3 diabetes mellitus,4 hypertension,5,6 and atrial 
fibrillation,7 which over time could lead to HF. The asso-
ciation between dietary magnesium with HFrEF but not 
HFpEF in our subgroup analysis is unique and requires 
further exploration of mechanisms. A 1- time infusion 
of elemental magnesium has been shown to acutely 
decreased LV filling pressures,26 while the long- term 
effects of magnesium intake on the myocardium is not 
known. We postulate that the relationship between 
magnesium intake and HFrEF but not HFpEF may 
be in part explained by the vascular dilation effects 
of magnesium,27 which mirrored the past vasodilator 
trials with angiotensin- converting enzyme inhibitors,28 
angiotensin receptor blockers,29 and hydralazine and 
nitrates30,31 and improved outcomes in patients with 
HFrEF but not HFpEF.32,33 Hemodynamically, vaso-
dilation using intravenous nitroprusside improved 
stroke volume in HFrEF but in much less magnitude in 
HFpEF.34 Similarly, isosorbide did not significantly im-
prove 6- minute walk distance or quality of life in partic-
ipants with HFpEF.33
Figure  2. Hazard ratios (95% CI) of incident hospitalization for HFpEF) and HFrEF in 2010 subcohort by quartiles of 
unadjusted and residual magnesium intake, respectively.
Model adjusted for age, smoking status, and traditional risk factors (BMI, systolic blood pressure, prior coronary heart disease, 
atrial fibrillation, heart rate, hypertension, diabetes mellitus, dyslipidemia), dietary intake (sodium, potassium, calcium, alcohol, 
protein, phosphorus, calibrated total energy [not included in the analysis using the residual method]), medications (angiotensin- 
converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium- containing laxatives, proton pump inhibitors), and 
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Based on the US Recommended Daily Allowance 
of dietary magnesium of 320 mg per day for nonpreg-
nant women >30 years of age, the implications of our 
study are large, as ≈75% of postmenopausal women in 
this multicenter, multiracial cohort study have a mag-
nesium intake (median, 272 mg for quartile 3) below 
Recommended Daily Allowances levels,10 and our re-
sults suggest that a quarter of the postmenopausal 
women in this cohort are at increased risk of incident 
HF on the basis of their dietary magnesium intake. Our 
total magnesium intake analysis, which incorporated 
magnesium supplements, showed slight attenuation of 
the association between dietary magnesium and inci-
dent HF and could serve as preliminary data to explore 
how supplemental magnesium intake may attenuate 
the risk of HF. In addition, the ARIC (Atherosclerosis 
Risk in Communities) cohort demonstrated that low 
serum magnesium levels were associated with the de-
velopment of incident HF.35 It is plausible that habitu-
ally high intake of magnesium may eventually increase 
serum magnesium levels as a reflection of higher body 
stores to provide protective effects against HF.36 Future 
studies are needed to further explore how magnesium 
supplementation may relate to HF risk.
Strengths of the current analysis include data from 
a large multiethnic prospective cohort of postmeno-
pausal women that allowed for greater generalizability. 
The use of validated dietary data and a high- quality 
HF outcome adjudication process would facilitate fu-
ture replication of our findings. The readjudication 
process in the WHI HF subtype cohort also allowed 
the secondary analysis examining HFpEF and HFrEF 
separately. We used inverse probability weighing to 
account for potential selection bias in the WHI cohort 
assembly subtypes. There were also limitations to this 
study. Despite our careful consideration of potential 
confounders, there is always the possibility of residual 
and/or unmeasured confounding. The dietary magne-
sium intake was only quantified at baseline and did not 
account for variations in magnesium intake over time 
and may have attenuated the results given the long 
duration of follow- up. The baseline HF criteria for ex-
clusion into the study sample are based on self- report, 
which is low in sensitivity (28%–38%) but high in speci-
ficity (96%–97%)37 and may lead to a nonselective mis-
classification bias and dilute the association between 
magnesium intake and incident HF hospitalizations. 
Additionally, data on kidney function were limited to 
only 10% of our study sample, for which adjustment 
for and interaction with kidney function in the analyses 
were not feasible. Finally, our analyses were restricted 
to women and thus not generalizable to men, but 
there has been no evidence that a clinically meaningful 
difference by sex exists on the association between 
dietary8 or serum magnesium and cardiovascular end 
points.35,38–40
In conclusion, we demonstrated that low dietary 
magnesium in a multicenter, multiracial cohort of post-
menopausal women was associated with a higher risk 
of incident HF, especially HFrEF.
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Table S1. Sub-models of Hazard ratio of incident hospitalized HF (2005) by quartiles (Q) of magnesium 
intake using unadjusted, residual and total intake methods of magnesium intake 
quantification 
Unadjusted baseline dietary magnesium intake quartiles* (N = 97,725) 
 Q1 Q2 Q3 Q4  
N 21,869 25,002 25,475 25,379  
HF cases 522 558 551 522  
HF incidence† 3.10 (3.09, 3.12) 2.84 (2.83, 2.86) 2.73 (2.72, 2.74) 2.59 (2.57, 2.60)  
  Hazard Ratio (95% CI)  p for trend 
Unadjusted 1.20 (1.06, 1.36) 1.10 (0.98, 1.24) 1.06 (0.94, 1.19) referent <0.01 
Model 1 1.15 (1.02, 1.30) 1.07 (0.95, 1.21) 1.02 (0.90, 1.15) referent 0.02 
Model 2 1.10 (0.97, 1.24) 1.04 (0.92, 1.18) 0.99 (0.88, 1.12) referent 0.12 
Model 3 1.14 (1.00, 1.29) 1.06 (0.94, 1.21) 1.01 (0.89, 1.14) referent 0.04 
Model 4 1.35 (1.04, 1.75) 1.19 (0.97, 1.46) 1.09 (0.92, 1.28) referent 0.02 
Model 5 1.32 (1.02, 1.71) 1.17 (0.96, 1.44) 1.08 (0.92, 1.27) referent 0.03 
      
Residual baseline dietary magnesium intake (regression on calibrated total energy intake)‡
 
(N=97,237)§  
Q1 Q2 Q3 Q4 
N 22,930 24,004 24,861 25,442 
HF cases 548 509 532 550 
HF incidence† 3.09 (3.08, 3.11) 2.70 (2.68, 2.71) 2.70 (2.69, 2.72) 2.73 (2.72, 2.74) 
 
Hazard Ratio (95% CI) p for trend 
Unadjusted 1.13 (1.01, 1.27) 0.99 (0.88, 1.11) 0.99 (0.88, 1.12) referent 0.08 
Model 1 1.38 (1.23, 1.56) 1.08 (0.95, 1.21) 1.02 (0.90, 1.14) referent <0.01 
Model 2 1.13 (1.00, 1.28) 0.99 (0.88, 1.12) 0.97 (0.86, 1.10) referent 0.09 
Model 3 1.18 (1.04, 1.33) 1.00 (0.88, 1.13) 0.98 (0.86, 1.10) referent 0.02 
Model 4 1.35 (1.06, 1.73) 1.10 (0.91, 1.35) 1.05 (0.90, 1.23) referent 0.02 
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Unadjusted baseline total magnesium intake (dietary and supplemental magnesium)|| (N = 97,725) 
 Q1 Q2 Q3 Q4  
N 21,683 24,368 25,555 26,119  
HF cases 556 558 514 525  
HF incidence† 3.32 (3.30, 3.33) 2.91 (2.89, 2.92) 2.54 (2.53, 2.55) 2.54 (2.53, 2.55)  
  Hazard Ratio (95% CI)  p for trend 
Unadjusted 1.30 (1.15, 1.46) 1.14 (1.01, 1.28) 1.00 (0.88, 1.13) referent <0.01 
Model 1 1.29 (1.14, 1.45) 1.11 (0.98, 1.25) 0.97 (0.86, 1.10) referent <0.01 
Model 2 1.19 (1.05, 1.34) 1.08 (0.95, 1.22) 0.95 (0.84, 1.07) referent <0.01 
Model 3 1.19 (1.05, 1.35) 1.06 (0.93, 1.20) 0.94 (0.83, 1.07) referent 0.01 
Model 4 1.29 (1.08, 1.54) 1.11 (0.95, 1.29) 0.97 (0.85, 1.11) referent 0.01 
Model 5 1.26 (1.03, 1.56) 1.09 (0.93, 1.29) 0.96 (0.84, 1.11) referent 0.06 
Models stratified by Observational Study/Hormone Trial membership 
Model 1 adjusted for age; 
Model 2 adjusted for age, race, smoking status, BMI, and dyslipidemia; 
Model 3 was model 2 + prior coronary heart disease, atrial fibrillation, heart rate, hypertension, and diabetes; 
Model 4 was Model 3 + dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy); 
calibrated total energy as a variable was not included in the analysis using the Residual method 
Model 5 (full model) was Model 4 + medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
diuretics, Mg containing laxatives, proton pump inhibitors) and multivitamins. 
 
   * range of dietary magnesium (mg/day) by quartiles: Q1: 0 to 181; Q2: 182 to 241; Q3: 242 to 309; Q4: 310 to 1004 
† incidence rate per 1000 person-years follow up (95% CI) 
‡ range of residual dietary magnesium by quartiles: Q1: -276 to -68; Q2: -67 to -12; Q3: -11 to 54; Q4: 55 to 750 
§ Sample size changed due to missingness in some variables used to calibrate total energy intake. 
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Table S2. Baseline Characteristics of Heart Failure Type, 2010 Sub-cohort (n=18,745). 
Un-calibrated baseline dietary magnesium intake quartiles 
 Q1 Q2 Q3 Q4 
N 5905 4755 4082 4003 
Magnesium median 
(mg/day) 
143 211 271 366 
HF cases 250 280 233 222 
HF incidence* 3.55 (3.53, 3.58) 4.60 (4.58, 4.63) 4.05 (4.03, 4.08) 4.09 (4.06, 4.11) 
Age (years) continuous 
      mean (SD) 62.4 (7.3) 62.7 (7.4) 63.0 (7.3) 62.8 (7.4) 
Age (years) categorical     
      <50 - 59 2218 (37.6) 1742 (36.6) 1434 (35.1) 1472 (36.8) 
      60 - 69 2584 (43.8) 2047 (43.1) 1764 (43.2) 1671 (41.7) 
      70 - ≥79 1103 (18.7) 966 (20.3) 884 (21.7) 860 (21.5) 
Race     
American Indian 13 (0.2) 8 (0.2) 11 (0.3) 10 (0.3) 
      Asian 60 (1.0) 49 (1.0) 39 (1.0) 30 (0.8) 
      Black 2903 (49.2) 1793 (37.7) 1322 (32.4) 1316 (32.9) 
      Hispanic 1258 (21.3) 935 (19.7) 690 (16.9) 746 (18.7) 
      White 1635 (27.7) 1945 (40.9) 1992 (48.9) 1873 (46.8) 
      Other 27 (0.5) 22 (0.5) 22 (0.5) 26 (0.7) 
Education     
     <High School 954 (16.4) 533 (11.3) 390 (9.7) 375 (9.5) 
     High School 1932 (33.1) 1423 (30.3) 1128 (27.9) 945 (23.9) 
     Some College 1468 (25.2) 1253 (26.7) 1064 (26.3) 1029 (26.0) 
     ≥College 1480 (25.4) 1490 (31.7) 1461 (36.1) 1605 (40.6) 
Income     
      <20,000 1817 (30.8) 1100 (23.1) 878 (21.5) 900 (22.5) 
20,000 - <35,000 1325 (22.4) 1158 (24.4) 1011 (24.8) 960 (24.0) 
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50,000 - <75,000 791 (13.4) 719 (15.1) 671 (16.4) 617 (15.4) 
       >75,000 479 (8.1) 513 (10.8) 507 (12.4) 474 (11.8) 
       Missing 507 (8.6) 375 (7.9) 302 (7.4) 275 (6.9) 
Smoking status     
       Never 3050 (52.6) 2381 (51.0) 2034 (50.7) 2053 (52.4) 
       Past 1980 (34.2) 1808 (38.7) 1608 (40.1) 1574 (40.1) 
       Current 767 (13.2) 481 (10.3) 371 (9.2) 295 (7.5) 
   Body Mass Index  (kg/m2)    
       mean (SD) 29.4 (6.4) 29.0 (6.1) 29.0 (6.2) 29.4 (6.5) 
Weight (kg)     
       mean (SD) 76.3 (18.2) 75.6 (17.5) 76.0 (17.6) 77.3 (18.5) 
Heart rate (beats per minute) 
       mean (SD) 70 (12.5) 70 (12.6) 70 (11.5) 
Systolic Blood Pressure (mm Hg) 
       mean (SD) 130 (18.3) 129 (17.5) 129 (17.9) 129 (17.7) 
Diastolic Blood pressure (mm Hg) 
       mean (SD) 77 (9.6) 76 (9.2) 76 (9.5) 76 (9.4) 
Waist/Hip Ratio     
       mean (SD) 0.82 (0.08) 0.82 (0.08) 0.82 (0.08) 0.82 (0.08) 
Total energy expenditure from recreational physical activity (METS/week) 
       mean (SD) 9.2 (12.5) 11.6 (13.6) 12.2 (14.2) 14.0 (15.4) 
Dietary magnesium intake (mg/day) 
       mean (SD) 138.9 (29.0) 211.0 (16.9) 272.2 (19.1) 388.4 (75.4) 
Total magnesium intake (mg/day) 
       mean (SD) 182.1 (116.7) 265.1 (123.6) 329.3 (130.2) 447.2 (147.4) 
Potassium (mg/day)     
       mean (SD) 1462.2 (364.1) 2180.8 (334.5) 2775.9 (404.4) 3862.4 (880.5) 
Calcium intake (mg/day) 
       mean (SD) 400.3 (175.5) 632.1 (230.3) 838.9 (294.9) 1272.8 (530.7) 
Dietary protein intake (grams) 
       mean (SD) 39.56 (12.9) 56.9 (15.6) 72.0 (18.7) 101.9 (32.6) 
Dietary phosphorus intake (mg) 
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Vitamin D (mcg/d)     
     mean (SD) 2.1 (1.3) 3.4 (1.8) 4.4 (2.4) 6.8 (4.3) 
Sodium intake (mg/day) 
     mean (SD) 1618.5 (524.3) 2301.4 (644.4) 2875.0 (774.7) 4094.6 (1394.3) 
Alcohol (servings/wk) 
     mean (SD) 1.27 (3.66) 1.80 (4.28) 2.31 (5.43) 2.73 (7.04) 
Calibrated total energy (kcal/day) 
     mean (SD) 2272 (284.5) 2301 (280.0) 2326 (284.1) 2382 (313.5) 
Hypertension     
     Yes 2431 (43.1) 1772 (39.2) 1464 (37.9) 1452 (38.3) 
Diabetes mellitus     
     Yes 490 (8.3) 363 (7.7) 286 (7.0) 311 (7.8) 
Dyslipidemia     
     Yes 485 (8.2) 434 (9.1) 371 (9.1) 303 (7.6) 
Previous coronary heart disease 
     Yes 467 (7.9) 368 (7.7) 306 (7.5) 263 (6.6) 
Atrial fibrillation     
     Yes 249 (4.2) 161 (3.4) 149 (3.7) 158 (4.0) 
Angiotensin receptor blockers 
     Yes 41 (0.7) 36 (0.8) 20 (0.5) 20 (0.5) 
Angiotensin converting enzyme inhibitors 
     Yes 601 (10.2) 447 (9.4) 335 (8.2) 298 (7.4) 
Multivitamin     
     Yes 1607 (27.2) 1534 (32.3) 1398 (34.3) 1442 (36.0) 
Diuretics     
     Yes 1074 (18.2) 821 (17.3) 621 (15.2) 586 (14.6) 
Laxatives containing magnesium 
     Yes 15 (0.3) 8 (0.2) 5 (0.1) 3 (0.1) 
Proton pump inhibitors 
     Yes 129 (2.2) 112 (2.4) 70 (1.7) 60 (1.5) 
* incidence rate per 1000 person-years follow up (95% CI) 
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Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation, 
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy), 
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, magnesium containing laxatives, proton pump 
inhibitors) and multivitamins. 
* incidence rate per 1000 person-years follow up (95% CI) 
   
 
  
Table S3. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of unadjusted 
magnesium intake. 
 
Heart Failure with preserved Ejection Fraction (HFpEF) 
  Unadjusted baseline dietary magnesium intake 
 Q1 Q2 Q3 Q4  
N 5905 4755 4082 4003  
HFpEF cases  121 155 133 119  
HFpEF incidence* 1.81 (1.80, 1.82) 2.63 (2.61, 2.64) 2.30 (2.29, 2.32) 2.24 (2.23, 2.26)   
 HR (95% CI) p for trend 
Unadjusted 0.85 (0.70, 1.02) 1.19 (1.00, 1.42) 1.02 (0.86, 1.22) referent 0.37 
Fully-Adjusted 0.74 (0.49, 1.12) 1.09 (0.80, 1.49) 0.97 (0.75, 1.24) referent 0.31 
 
Heart Failure with reduced Ejection Fraction (HFrEF) 
  Unadjusted baseline dietary magnesium intake 
 Q1 Q2 Q3 Q4  
N 5905 4755 4082 4003  
HFrEF cases  86 72 71 64  
HFrEF incidence* 1.18 (1.17, 1.19) 1.18 (1.17, 1.19) 1.28 (1.27, 1.28) 1.13 (1.13, 1.14)   
 HR (95% CI) p for trend 
Unadjusted 1.08 (0.84, 1.38) 1.06 (0.83, 1.36) 1.13 (0.88, 1.44) referent 0.65 
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Table S4. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of residual 
magnesium intake after regression on calibrated total energy intake 
 
Heart Failure with preserved Ejection Fraction (HFpEF) 
  Residual baseline dietary magnesium intake (adjusted for calibrated energy) 
 Q1 Q2 Q3 Q4  
N* 6337 4528 3951 3868  
HFpEF cases  140 129 148 109  
HFpEF incidence† 1.95 (1.94, 1.96) 2.24 (2.23, 2.25) 2.69 (2.67, 2.70) 2.14 (2.13, 2.16)   
 HR (95% CI) p for trend 
Unadjusted 0.94 (0.79, 1.13) 1.06 (0.88, 1.27) 1.25 (1.04, 1.49) referent 0.30 
Fully-Adjusted 0.97 (0.65, 1.46) 1.07 (0.78, 1.47) 1.21 (0.94, 1.55) referent 0.73 
 
Heart Failure with reduced Ejection Fraction HFrEF  
  Residual baseline dietary magnesium intake (adjusted for calibrated energy) 
 Q1 Q2 Q3 Q4  
N* 6337 4528 3951 3868  
HFrEF cases  84 76 67 64  
HFrEF incidence† 1.07 (1.06, 1.07) 1.33 (1.32, 1.34) 1.23 (1.22, 1.24) 1.17 (1.17, 1.18)   
 HR (95% CI) p for trend 
Unadjusted 0.93 (0.73, 1.20) 1.15 (0.90, 1.46) 1.05 (0.82, 1.36) referent 0.09 
Fully-Adjusted 1.81 (1.08, 3.05) 1.90 (1.26, 2.86) 1.28 (0.91, 1.80) referent 0.01 
Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation, 
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy), 
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, Mg containing laxatives, proton pump 
inhibitors) and multivitamins. 
* Sample size changed due to missingness in some variables used to calibrate total energy intake. 
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Model adjusted for age, race, smoking status, BMI, and dyslipidemia, systolic blood pressure, prior coronary heart disease, atrial fibrillation, 
heart rate, hypertension, and diabetes, dietary intake (sodium, potassium, calcium, alcohol, protein, phosphorus, calibrated total energy), 
medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, Mg containing laxatives, proton pump 
inhibitors) and multivitamins. 
* incidence rate per 1000 person-years follow up (95% CI) 




Table S5. Hazard ratio of incident hospitalized preserved & reduced heart failure in 2010 sub-cohort by quartiles (Q) of total 
magnesium intake (accounting for magnesium supplements). 
 
Heart Failure with preserved Ejection Fraction (HFpEF) 
  Unadjusted total dietary magnesium intake 
 Q1 Q2 Q3 Q4  
N 6137 4819 4100 3689  
HFpEF cases  146 131 147 104  
HFpEF incidence* 2.13 (2.12, 2.14) 2.11 (2.10, 2.12) 2.66 (2.64, 2.68) 2.07 (2.06, 2.09)   
 HR (95% CI) p for trend 
Unadjusted 1.08 (0.90, 1.30) 1.03 (0.85, 1.24) 1.28 (1.07, 1.54) referent 0.82 
Fully-Adjusted 1.25 (0.89, 1.76) 1.11 (0.85, 1.45) 1.25 (1.01, 1.56) referent 0.24 
 
Heart Failure with reduced Ejection Fraction HFrEF  
  Unadjusted total dietary magnesium intake 
 Q1 Q2 Q3 Q4  
N 6137 4819 4100 3689  
HFrEF cases  86 83 65 59  
HFrEF incidence* 1.11 (1.10, 1.12) 1.34 (1.33, 1.35) 1.15 (1.14, 1.16) 1.17 (1.16, 1.17)   
 HR (95% CI) p for trend 
Unadjusted 0.99 (0.77, 1.27) 1.16 (0.91, 1.47) 0.98 (0.76, 1.27) referent 0.76 
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